Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04556292

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Breast Cancer Metastatic Clinical Trial

Official title:
A Phase 2, Open-Label, Multi-Center Study of SC10914 in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received More Than 2 Prior Chemotherapy Regimens for Metastatic Disease

Clinical Trial Summary

This open label, multi-centre phase II study will assess the efficacy and safety of single agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04556292
Study type Interventional
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact zhang qingsheng, MD,PhD
Phone 13913886090
Email zhangqinsheng@sh-qingfeng.net
Status Recruiting
Phase Phase 2
Start date August 12, 2020
Completion date August 30, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04509596 - DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer Phase 1
Not yet recruiting NCT05800275 - Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT04122469 - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease N/A
Completed NCT03045653 - Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer Phase 2
Active, not recruiting NCT03322215 - HR+/HER2- Advanced Breast Cancer and Endocrine Resistance Phase 2
Active, not recruiting NCT04059484 - Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer Phase 2
Recruiting NCT04368442 - Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
Active, not recruiting NCT03709082 - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Phase 1/Phase 2
Terminated NCT03642990 - NR in Chemo-induced Peripheral Neuropathy Phase 2
Terminated NCT01876251 - A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Recruiting NCT03086785 - Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer Phase 2
Terminated NCT04197999 - A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Phase 1
Not yet recruiting NCT03638765 - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer Phase 1
Completed NCT05609903 - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
Recruiting NCT04597580 - Personalised Disease Monitoring in Metastatic Breast Cancer
Not yet recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1